Orange Bridge’s A.B.R.E.S. Bitcoin Real Estate Certification Marks Two-Year Milestone “`

SAN DIEGO, Feb. 13, 2025 — Orange Bridge celebrates two years of its Accredited Bitcoin Real Estate Specialist (A.B.R.E.S.) certification program, equipping agents with the expertise to navigate the Bitcoin-real estate market. This program helps agents understand Bitcoin's potential benefits for clients, leading to increased listings, sales, and competitive advantage. “This…

Barclays Q4 2024 Financial Results “`

Barclays' fourth-quarter 2024 financial results reveal strong growth alongside emerging challenges. The bank achieved substantial revenue gains, largely due to its investment banking arm's increased trading activity and client engagements. However, heightened regulatory oversight and rising operational expenses presented obstacles. Investment banking significantly boosted Barclays' performance, with a 15% year-over-year…

JioCinema and Virtual 5G Express Plus Partner for Global OTT Access; Marketing Campaign Launched “`

SINGAPORE, Feb. 13, 2025 — Virtual Internet launched a joint solution featuring JioCinema and Virtual 5G Express Plus. This marketing campaign, targeting JioCinema users, highlights the global accessibility of services enabled by Virtual 5G Express Plus. The campaign will utilize a multi-platform approach, encompassing both social and traditional media.    …

SoftBank Reports Q3 Losses Amid Market Volatility “`

SoftBank Group's third-quarter results surprised investors with a substantial net loss, a consequence of volatile market conditions impacting its investment strategy. This outcome contradicts analysts' predictions of a profitable quarter, highlighting the difficulties SoftBank faces navigating current global economic challenges affecting its significant investments. The Vision Fund, renowned for significant…

DAAN Biotherapeutics and LigaChem Biosciences Partner on Exclusive Antibody Licensing for ADC Development

SEOUL, South Korea, Feb. 13, 2025 — DAAN Biotherapeutics, a leading innovator in TCR-based therapies, has granted LigaChem Biosciences exclusive rights to a novel, tumor-targeting antibody. This agreement will advance the development and market launch of Antibody-Drug Conjugates (ADCs). This collaboration allows LigaChem Biosciences to significantly progress its ADC development…